Prostate Cancer Screening: Knowledge, Attitudes, and Practices by Medical Doctors in Portugal
- PMID: 40533657
- DOI: 10.1007/s13187-025-02665-4
Prostate Cancer Screening: Knowledge, Attitudes, and Practices by Medical Doctors in Portugal
Abstract
Opportunistic prostate cancer (PCa) screening is common worldwide, with physicians playing an important role in its uptake and consequences. This study explores the knowledge, attitudes, and practices of family doctors and urologists in Portugal regarding PCa screening. A national online survey was conducted between November 2020 and February 2021. Family doctors and urologists were reached by email through their national medical associations, for a total of 596 and 63 participants from each group, respectively. Urologists considered themselves more updated with PCa screening practices than family doctors (93.0% vs. 73.1%; p < 0.001). Family doctors were more likely to consider older age (97.2% vs. 90.9%; p = 0.025) and smoking (80.6% vs. 31.7%; p < 0.001) as risk factors for PCa. Most urologists reported following the European Association of Urology Guidelines for PCa screening (90.9%), while family doctors preferred the National Guidelines (73.9%). A higher proportion of urologists believed early diagnosis is essential for improving PCa prognosis (92.9% vs. 67.9%; p < 0.001). Urologists were more likely to recommend prostate-specific antigen (PSA) testing for age group-eligible males (always or almost always: 77.2% vs. 20.4%; p < 0.001) and to perform digital rectal examination (never or rarely: 3.5% vs. 96.2%; p < 0.001). Overall, 65.1% of doctors believed that magnetic resonance imaging could improve the diagnosis of PCa in patients with high PSA levels. Family doctors and urologists differed in their knowledge, attitudes, and practices regarding PCa screening. The latter are more interventive and believe more in the benefits of PCa screening.
Keywords: Early detection of cancer; Family physicians; Prostate-specific antigen; Prostatic neoplasm; Urologists.
© 2025. The Author(s) under exclusive licence to American Association for Cancer Education.
Conflict of interest statement
Declarations. Ethical Approval: The study was approved by the Ethics Committee of the Instituto de Saúde Pública da Universidade do Porto (Parecer nº CE20168) and by both Medical Associations (Associação Portuguesa de Medicina Geral e Familiar and Associação Portuguesa de Urologia). All data collected were anonymous, and no information was requested to identify the participants. All procedures were followed by the ethical standards of the institutional and/or national research committee, along with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical Review Board: The Ethics Committee of the Instituto de Saúde Pública da Universidade do Porto (Parecer nº CE20168) approved the study protocol. Informed Consent: Participants provided written informed consent by agreeing to participate in the online survey. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Perspectives of clinicians and screening candidates on shared decision-making in prostate cancer screening with the prostate-specific antigen (PSA) test: a qualitative study (PROSHADE study).BMJ Evid Based Med. 2025 May 20;30(3):163-172. doi: 10.1136/bmjebm-2024-113113. BMJ Evid Based Med. 2025. PMID: 39797674 Free PMC article.
-
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1. MMWR Surveill Summ. 2025. PMID: 40493548 Free PMC article.
-
Global Delphi consensus on treatment goals for generalized pustular psoriasis.Br J Dermatol. 2025 Mar 18;192(4):706-716. doi: 10.1093/bjd/ljae491. Br J Dermatol. 2025. PMID: 39844356
-
Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.J Parkinsons Dis. 2025 Jun;15(4):789-804. doi: 10.1177/1877718X251330993. Epub 2025 Apr 29. J Parkinsons Dis. 2025. PMID: 40302366
-
Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression.Br J Dermatol. 2024 Jun 20;191(1):24-35. doi: 10.1093/bjd/ljae011. Br J Dermatol. 2024. PMID: 38197404
References
-
- Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.21834 - DOI - PubMed
-
- Cornford P et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148–163. https://doi.org/10.1016/j.eururo.2024.03.027 - DOI - PubMed
-
- Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, ERSPC investigators (2014) The European Randomized Study of Screening for Prostate Cancer – prostate cancer mortality at 13 years of follow-up. Lancet 384(9959):2027–2035. https://doi.org/10.1016/S0140-6736(14)60525-0 - DOI - PubMed - PMC
-
- Grossman DC et al (2018) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319(18):1901–1913. https://doi.org/10.1001/jama.2018.3710 - DOI - PubMed
-
- Hugosson J et al (2019) A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol 76(1):43–51. https://doi.org/10.1016/j.eururo.2019.02.009 - DOI - PubMed - PMC
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous